Kaliumjodide G.L. (Potassium Iodide)

Potassium iodide provides a large amount of stable iodide ions that are quickly absorbed after oral administration. The excess iodide fills the sodium‑iodide symporter in thyroid cells, competitively blocking the uptake of radioactive iodine isotopes. This reduces the amount of radiation the thyroid receives, offering temporary protection during exposure.

The appropriate dose of Kaliumjodide G.L. is determined by a qualified prescriber based on the specific clinical scenario, patient age, weight, and the level of radioactive exposure. Healthcare professionals follow national or international guidelines to calculate the correct amount for each individual case.

Safety data for potassium iodide in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs any possible risk to the mother or infant. Pregnant or breastfeeding individuals should discuss the need for thyroid protection with their healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kaliumjodide G.L. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kaliumjodide G.L. is comparable to other stable iodine products such as potassium iodide tablets (e.g., SSKI) in its mechanism of thyroid blocking. Differences may lie in formulation, manufacturing standards, and regulatory approvals. GNH India’s product meets EU quality standards and is supplied under Good Distribution Practice, ensuring consistent potency and safety.

Store Kaliumjodide G.L. at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity, which could affect tablet integrity.

Kaliumjodide G.L. is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Administration is typically performed as soon as possible after a known or suspected exposure to radioactive iodine.

Serious risks include allergic reactions such as anaphylaxis, iodide‑induced hyperthyroidism, severe skin eruptions, and, in rare cases, pulmonary edema. Patients with pre‑existing thyroid disorders, autoimmune thyroid disease, or certain cardiac conditions should be closely monitored for these potential complications.

Kaliumjodide G.L. should be avoided in individuals with known hypersensitivity to potassium iodide or any excipients in the tablet. Patients with uncontrolled hyperthyroidism, severe iodine allergy, or certain renal impairments should not use the product without medical supervision. Always consult a healthcare professional before initiating therapy.